Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gastric Cancer
  Free Subscription

Articles published in
Br J Cancer
    September 2026
  1. HIRANO H, Yamada Y, Nagashima K, Hiraoka N, et al
    PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.
    Br J Cancer. 2026 Sep 4. doi: 10.1038/s41416-026-03607.
    >> Share

  2. YUAN J, Gong J, Peng Z, Liu TS, et al
    Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.
    Br J Cancer. 2026;135:924-930.
    >> Share

    August 2026
  3. HONG Y, Hwang I, Kim MJ, Kim Y, et al
    A deep learning-derived risk score model from digital pathology to forecast nivolumab outcomes in gastric carcinoma.
    Br J Cancer. 2026 Aug 21. doi: 10.1038/s41416-026-03590.
    >> Share

    July 2026
  4. GORDON A, Tran A, Fong C, Cromarty S, et al
    Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial.
    Br J Cancer. 2026;135:240-247.
    >> Share

  5. FLANDERS L, Savy T, Ficial M, Al-Ghraibawi N, et al
    PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation.
    Br J Cancer. 2026;135:232-239.
    >> Share

    June 2026
  6. GUO J, Cai F, Zhang M, Nie X, et al
    LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation.
    Br J Cancer. 2026 Jun 17. doi: 10.1038/s41416-026-03496.
    >> Share

    May 2026
  7. SHE H, Xiang T, Wang J, Lin Z, et al
    Deep learning-based prediction of lymph node metastasis and occult tumor cells in gastric cancer using histopathological images: a retrospective study.
    Br J Cancer. 2026 May 19. doi: 10.1038/s41416-026-03400.
    >> Share

  8. KAMP D, May AM, van Velzen MJM, Mook S, et al
    Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic gastroesophageal adenocarcinoma.
    Br J Cancer. 2026;134:1420-1428.
    >> Share

    April 2026
  9. GU Y, Wang J, Ling Z, Liu J, et al
    Lethal clinical outcome and immune desert contexture in refractory gastric cancer harboring CCNE1 amplification and overexpression.
    Br J Cancer. 2026 Apr 28. doi: 10.1038/s41416-026-03461.
    >> Share

    March 2026
  10. KWAK Y, Kim TY, Lee HS, Nam SK, et al
    Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer.
    Br J Cancer. 2026 Mar 27. doi: 10.1038/s41416-026-03405.
    >> Share

    February 2026
  11. LI P, Chen H, Chen S, Mo X, et al
    Retraction Note: Circular RNA 0000096 affects cell growth and migration in gastric cancer.
    Br J Cancer. 2026 Feb 10. doi: 10.1038/s41416-026-03351.
    >> Share

    January 2026
  12. LUO Y, Peng H, Yao Q, Xie Y, et al
    Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer.
    Br J Cancer. 2026 Jan 26. doi: 10.1038/s41416-025-03290.
    >> Share

  13. LIN JX, Yoon C, Li P, Ryeom SW, et al
    Retraction Note: CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer.
    Br J Cancer. 2026 Jan 20. doi: 10.1038/s41416-026-03338.
    >> Share

  14. SHI DB, Qin YC, Liu S, Zhao RN, et al
    INHBA, regulated by C/EBPbeta, induces M2 macrophage polarization to promote tumor metastasis and growth via activating the PI3K/AKT pathway in gastric cancer.
    Br J Cancer. 2026 Jan 15. doi: 10.1038/s41416-025-03326.
    >> Share

  15. BILSLAND AE, McCulloch E, Degerman S, Landfors M, et al
    Relative telomere length and senescence-associated inflammatory cytokines as blood-based prognostic markers in patients with advanced or resectable gastro-oesophageal adenocarcinoma.
    Br J Cancer. 2026;134:208-217.
    >> Share

    November 2025
  16. LI J, Liu L, Tao M, Han Z, et al
    Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer.
    Br J Cancer. 2025 Nov 29. doi: 10.1038/s41416-025-03289.
    >> Share

  17. LEE KW, Zang DY, Kim HD, Kim JW, et al
    Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
    Br J Cancer. 2025 Nov 11. doi: 10.1038/s41416-025-03267.
    >> Share

    October 2025
  18. KIM TH, Lee D, Oh HJ, Ham IH, et al
    Cancer-associated fibroblast-derived GAS6 increases resistance to chemotherapy through AXL/STAT3/ABCG1 in gastric cancer.
    Br J Cancer. 2025 Oct 28. doi: 10.1038/s41416-025-03218.
    >> Share

  19. TIAN H, Liu M, Liu Z, Shi C, et al
    Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study.
    Br J Cancer. 2025;133:1038-1045.
    >> Share

    August 2025
  20. LI L, Yin J, Zhang L, Liu W, et al
    Aberrant PJA2-CHRM3 signaling creates a therapeutic vulnerability in gastric tumor.
    Br J Cancer. 2025 Aug 26. doi: 10.1038/s41416-025-03145.
    >> Share

  21. SHI D, Liu W, Sun L, Zhao X, et al
    LMP2A regulates S901 phosphorylation of EphA2 to maintain EBV latent infection in gastric cancer.
    Br J Cancer. 2025 Aug 9. doi: 10.1038/s41416-025-03131.
    >> Share

  22. WANG B, Wang Y, Zhu Y, Guo L, et al
    Predictive factors for neoadjuvant combined immunotherapy in gastric adenocarcinoma: Focusing on the primitive enterocyte phenotype and PVR.
    Br J Cancer. 2025;133:255-269.
    >> Share

    July 2025
  23. ZHOU J
    Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03100.
    >> Share

  24. YANG C, Gao Z, Tang R, Zhou L, et al
    POU6F2 promotes liver metastasis of gastric adenocarcinoma by dual mechanism of transcriptional upregulation of SNAI1 and IGF2/PI3K/AKT signaling-induced conversion of hepatic stellate cells into cancer-associated fibroblasts.
    Br J Cancer. 2025;133:14-26.
    >> Share

    June 2025
  25. ZHAO R, Xie J, Chen H, Gong X, et al
    VASN drives gastric tumorigenesis via activation of the COL4A1/PI3K/AKT axis during Helicobacter pylori infection.
    Br J Cancer. 2025 Jun 23. doi: 10.1038/s41416-025-03081.
    >> Share

  26. LEE KW, Zang DY, Kim HD, Kim JW, et al
    Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
    Br J Cancer. 2025 Jun 20. doi: 10.1038/s41416-025-03092.
    >> Share

    May 2025
  27. LEE KW, Zang DY, Kim HD, Kim JW, et al
    Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
    Br J Cancer. 2025 May 21. doi: 10.1038/s41416-025-03052.
    >> Share

  28. GROEN-VAN SCHOOTEN TS, Cabeza-Segura M, Ferreira RM, Martinez-Ciarpaglini C, et al
    Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence.
    Br J Cancer. 2025;132:783-792.
    >> Share

    April 2025
  29. SUN M, Gu Y, Wang J, Zhang Z, et al
    Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer.
    Br J Cancer. 2025 Apr 25. doi: 10.1038/s41416-025-03002.
    >> Share

  30. LI J, Tao M, Liu L, Liu C, et al
    Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer.
    Br J Cancer. 2025 Apr 17. doi: 10.1038/s41416-025-03015.
    >> Share

  31. LU J, Chen Y, Liu X, Wang J, et al
    Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration.
    Br J Cancer. 2025 Apr 15. doi: 10.1038/s41416-025-02984.
    >> Share

    March 2025
  32. TSUTSUMI C, Ohuchida K, Yamada Y, Shimada Y, et al
    Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment.
    Br J Cancer. 2025 Mar 24. doi: 10.1038/s41416-025-02981.
    >> Share

    September 2024
  33. CHEN C, Han J, He Q, Yao Q, et al
    Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.
    Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02835.
    >> Share

  34. KANDA M, Kasahara Y, Shimizu D, Shinozuka T, et al
    Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer.
    Br J Cancer. 2024 Sep 20. doi: 10.1038/s41416-024-02859.
    >> Share

    August 2024
  35. GU Y, Sun M, Fang H, Shao F, et al
    Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02825.
    >> Share

    July 2024
  36. FANG M, Lin Y, Xue C, Sheng K, et al
    The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis.
    Br J Cancer. 2024 Jul 13. doi: 10.1038/s41416-024-02778.
    >> Share

  37. HARA Y, Baba Y, Oda E, Harada K, et al
    Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02753.
    >> Share

  38. ANGERILLI V, Sabella G, Simbolo M, Lagano V, et al
    Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
    Br J Cancer. 2024;131:159-170.
    >> Share

    June 2024
  39. LI X, Xie G, Chen J, Wang Y, et al
    Tumour cell-derived serglycin promotes IL-8 secretion of CAFs in gastric cancer.
    Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02735.
    >> Share

    May 2024
  40. MURPHY JD, Gadalla SM, Anderson LA, Rabkin CS, et al
    Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom.
    Br J Cancer. 2024 May 22. doi: 10.1038/s41416-024-02714.
    >> Share

    March 2024
  41. SUH YS, Lee J, George J, Seol D, et al
    RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02642.
    >> Share

    February 2024
  42. SAITO T, Kurokawa Y, Fujitani K, Kawabata R, et al
    Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
    Br J Cancer. 2024 Feb 7. doi: 10.1038/s41416-023-02540.
    >> Share

  43. CECCHINI M, Cleary JM, Shyr Y, Chao J, et al
    NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
    Br J Cancer. 2024;130:476-482.
    >> Share

  44. GROSSER B, Emmerson J, Reitsam NG, Cunningham D, et al
    Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
    Br J Cancer. 2024;130:457-466.
    >> Share

    January 2024
  45. WANG J, Sun N, Kunzke T, Shen J, et al
    Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.
    Br J Cancer. 2024 Jan 24. doi: 10.1038/s41416-023-02559.
    >> Share

  46. CAI F, Yang X, Ma G, Wang P, et al
    EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-kappaB signalling activation independent of hydroxylase activity.
    Br J Cancer. 2024 Jan 6. doi: 10.1038/s41416-023-02546.
    >> Share

    December 2023
  47. KAMIYA H, Komatsu S, Takashima Y, Ishida R, et al
    Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.
    Br J Cancer. 2023 Dec 26. doi: 10.1038/s41416-023-02532.
    >> Share

    November 2023
  48. ALLAN Z, Witts S, Tie J, Tebbutt N, et al
    The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review.
    Br J Cancer. 2023;129:1717-1726.
    >> Share

    August 2023
  49. CHEN T, Li D, Wang Y, Shen X, et al
    Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1alpha-FBLN5 signaling pathway.
    Br J Cancer. 2023 Aug 29. doi: 10.1038/s41416-023-02409.
    >> Share

  50. ANDO K, Nakamura Y, Kitao H, Shimokawa M, et al
    Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
    Br J Cancer. 2023 Aug 2. doi: 10.1038/s41416-023-02378.
    >> Share

    July 2023
  51. LIU X, Lv K, Wang J, Lin C, et al
    C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02336.
    >> Share

  52. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    >> Share

    June 2023
  53. DONG X, Fan J, Xie W, Wu X, et al
    Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.
    Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02319.
    >> Share

    April 2023
  54. LIU DHW, Kim YW, Sefcovicova N, Laye JP, et al
    Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial.
    Br J Cancer. 2023 Apr 7. doi: 10.1038/s41416-023-02257.
    >> Share

  55. LAAKSONEN MA, Li S, Canfell K, MacInnis RJ, et al
    The future burden of oesophageal and stomach cancers attributable to modifiable behaviours in Australia: a pooled cohort study.
    Br J Cancer. 2023;128:1052-1069.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016